The Bull Market is Back: 3 Stocks to Buy Now (HIMS, APP, META)
Hims & Hers Health, AppLovin and Meta Platforms all boast a litany of bullish catalysts driving their stock prices higher.
Why Hims & Hers Health, Inc. (HIMS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hims & Hers expands into Europe with Zava acquisition
Hims & Hers (NYSE:HIMS), a leading US-based health and wellness platform, is expanding into Europe via its acquisition of telehealth platform and online pharmacy Zava. The company said the acquisition will expand its footprint in the UK and launch the company in Germany, France and Ireland, with additional markets expected soon.
Hims & Hers stock rockets on news of European launch
Hims & Hers Health (NYSE: HIMS) experienced a notable uptick in its stock price following the announcement of its planned acquisition of ZAVA, a prominent European digital health platform.
Hims & Hers to acquire European telehealth platform in global expansion
Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava. The deal will expand Hims' services to Ireland, France and Germany and will grow its active customer base by roughly 50%.
Hims & Hers: Still Huge Potential Ahead
Hims & Hers Health, Inc is a telehealth platform offering tailored health and wellness services, showing significant stock volatility recently. HIMS experienced a dramatic rise from $24.11 to $68.75 in February but has since settled at $49.47. Financials reveal a 111% YoY revenue increase to $586 million and a 77.5% rise in net income to $49.5 million.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Peptide And Short Squeeze Are Coming!
Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1, positioning itself as a leader in the biohacking and longevity markets. The company's strategic moves—acquiring a peptide facility, partnering with Novo Nordisk, and investing in AI-driven customization—create a strong competitive advantage and growth runway. With short interest at 34% and legal risks largely resolved, the stock is primed for a potential short squeeze and upward momentum, especially as valuation remains low.
What's Happening With HIMS Stock?
Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, following the announcement of a 4% reduction in its workforce. This move comes as the company responds to a U.S. ban, effective May 22nd, on the production of mass copies of the weight-loss medication, Wegovy.
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy
Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted stellar Q1 FY 2025: Revenue +110%, EBITDA +181%, EPS +300%. Growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Management's ambitious 2030 strategy leverages AI, new specialties, and global expansion, aiming for significant top-line and EPS growth.
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
Hims & Hers Health: New Guidance Creates Huge Risk For Shorts
Hims & Hers Health continues to fire on all cylinders as a business, growing at extraordinary rates while also improving its margins. Today, I will offer a unique and simplified view of the business based on its recently announced, and very important, deal with Novo Nordisk. In short, based on Hims multi-product and multi-brand platform, which has generated sustained free cash flow for years now alongside healthy growth, I believe there's still upside ahead.
